APA (7th ed.) Citation

V, P., BM, S., & RL, C. (2026). An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. Expert review of anticancer therapy, 1. https://doi.org/10.1080/14737140.2026.2665840

Chicago Style (17th ed.) Citation

V, Podder, Slomovitz BM, and Coleman RL. "An Evaluation of Avutometinib in Combination with Defactinib for KRAS-mutated Recurrent Low-grade Serous Ovarian Cancer." Expert Review of Anticancer Therapy 2026: 1. https://doi.org/10.1080/14737140.2026.2665840.

MLA (9th ed.) Citation

V, Podder, et al. "An Evaluation of Avutometinib in Combination with Defactinib for KRAS-mutated Recurrent Low-grade Serous Ovarian Cancer." Expert Review of Anticancer Therapy, 2026, p. 1, https://doi.org/10.1080/14737140.2026.2665840.